Search
Close this search box.
Search
Subscriber Log In

In Case You Missed It: Three Things we Learned in our World Preview Webinar

Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of the future of this ever-changing market, from the biggest drugs and players, to the therapy areas in growth or decline. The report is excellent (not […]

Who’s winning in the battle for efficient capital deployment?

Image of a productivity dial

Over the last ten years, large pharma companies have spent an average of $120bn across R&D and business development investments. The net result? Portfolios worth approximately $210bn, according to Evaluate’s net present value (NPV) methodology. However, within these averages lie dramatically diverging performances, highlighting the challenges of deploying capital efficiently. Overall company performance is heavily […]

What’s Behind Pharma’s Growth Boost?

2030 forecasts

One of the milestones in the Evaluate year is the publication of our annual World Preview report, now in its 17th year. If you’re not familiar with the piece, it’s a deep dive into the state of the biopharma market, using Evaluate’s pharma forecasts to uncover key trends, challenges and drivers of growth (or indeed […]